Precigen Inc
NASDAQ:PGEN

Watchlist Manager
Precigen Inc Logo
Precigen Inc
NASDAQ:PGEN
Watchlist
Price: 1.52 USD -16.94%
Market Cap: 448.7m USD

Operating Margin
Precigen Inc

-3 171%
Current
-1 400%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 171%
=
Operating Profit
-133.2m
/
Revenue
4.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Precigen Inc
NASDAQ:PGEN
448.6m USD
-3 171%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
332.6B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
165.1B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
139.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
128.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Precigen Inc
Glance View

Market Cap
448.6m USD
Industry
Biotechnology

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 456 full-time employees. The company went IPO on 2013-08-08. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The firm also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. The company also has a robust pipeline of preclinical programs.

PGEN Intrinsic Value
7.69 USD
Undervaluation 80%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 171%
=
Operating Profit
-133.2m
/
Revenue
4.2m
What is the Operating Margin of Precigen Inc?

Based on Precigen Inc's most recent financial statements, the company has Operating Margin of -3 171%.

Back to Top